Healthcare Services China

China Preclinical CRO Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

China Preclinical CRO Market Industry Trends and Forecast to 2034: Segmented by (Service, Model, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $560.6 Mn Placeholder estimate
Estimate 2025 $620.6 Mn 8.7% of the global market
Projected 2034 $1.55 Bn 149.6% Adds $928.7 Mn over 9 forecast years
CAGR 2025–2034 10.7% Faster than 50% of 109 Healthcare Services markets here
Key players 6 +1
  • China is 8.71% of the global market.
  • In APAC, the largest is China (this report) at $620.6 Mn.
  • Fastest growing: India at 12.1% a year.
  • China ranks 1st of 14 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$928.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Preclinical CRO Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $560.6 Mn — —
2025 (base) $620.6 Mn +$60.0 Mn —
2026 (forecast) $687.0 Mn +$66.4 Mn +10.7%
2027 (forecast) $760.5 Mn +$73.5 Mn +22.5%
2028 (forecast) $841.8 Mn +$81.4 Mn +35.7%
2029 (forecast) $931.9 Mn +$90.1 Mn +50.2%
2030 (forecast) $1.03 Bn +$99.7 Mn +66.2%
2031 (forecast) $1.14 Bn +$110.4 Mn +84%
2032 (forecast) $1.26 Bn +$122.2 Mn +103.7%
2033 (forecast) $1.40 Bn +$135.3 Mn +125.5%
2034 (forecast) $1.55 Bn +$149.7 Mn +149.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

China Preclinical CRO Market Analysis at a glance
Market size, 2025$620.6 Mn placeholder estimate
Forecast, 2034$1.55 Bn placeholder estimate
Growth (CAGR), 2025–203410.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsService and model (see all)
Key playersCharles River Laboratories, Labcorp, WuXi AppTec, Eurofins Scientific, Inotiv and 1 more (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The China Preclinical CRO Market Analysis Executive Summary

Preclinical contract research organizations run lab and animal studies on new drugs for safety and effect before they are tested in people.

Key segments of the preclinical CRO market include service (Toxicology Testing, Bioanalysis and Pharmacology) and model (In Vivo, In Vitro and In Silico).

Bar chart: China Preclinical CRO market size, 2024–2034, placeholder estimates. $560.6 Mn in 2024, $620.6 Mn in 2025 and $1.55 Bn in 2034, 10.7% CAGR.
China Preclinical CRO market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

China Preclinical CRO Market Dynamics

Market Growth Drivers

Drug makers are outsourcing more research, the pipeline of new drugs is growing and small biotech firms need partners with lab and trial skills, which drives the preclinical CRO market.

Opportunity

Data-driven trial design, new drug types such as cell and gene therapy and demand from Asian drug makers give the preclinical CRO market room to grow.

Market Restraints

Pressure on prices, difficulty finding trial patients and staff turnover at service firms hold back the preclinical CRO market.

Competitive Landscape for Preclinical CRO Market in China

The preclinical CRO market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Preclinical CRO Market in China

Preclinical CRO in China: payment

Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.⁠[1]

Policy changes and Reimbursement scenario

Licensing, quality standards and payment models from public and private payers shape how preclinical CRO services are delivered and paid for in China. Government health programs and insurance coverage are key to access.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Preclinical CRO right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 22 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Preclinical CRO in context

China compared

  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 6th highest of the 17 countries we cover in APAC.[1]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 14.9% of people (2025). World: 10.4% of people (2025). 7th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 22 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Preclinical CRO market in China?
Placeholder estimate: about $620.6 Mn in 2025, rising to about $1.55 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Preclinical CRO market in China growing?
Placeholder estimate: about 10.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Preclinical CRO market report cover?
The report splits the market by service (Toxicology Testing, Bioanalysis, Pharmacology, Drug Metabolism Studies) and model (In Vivo, In Vitro, In Silico).
Who are the key players in the Preclinical CRO market?
Key players include Charles River Laboratories, Labcorp, WuXi AppTec, Eurofins Scientific, Inotiv and Medpace.
What is driving the Preclinical CRO market?
Drug makers are outsourcing more research, the pipeline of new drugs is growing and small biotech firms need partners with lab and trial skills, which drives the preclinical CRO market.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
Back to Catalogue

Related Healthcare Services reports in China

See all

Related on clinical trials and drug development and manufacturing

See the topic